Starting January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is rolling out a major new payment model called the Transforming Episode Accountability Model, or TEAM. This program will change how hospitals get paid for certain surgeries – and it’s something hospitals need to start preparing for now. Understanding what it is, who…

Healthcare is evolving. We used to focus purely on addressing specific symptoms and treating specific diseases. Our understanding of medicine and medical care was shaped by biology and what goes on inside the body.  But we now know that our health outcomes are also significantly shaped by external factors – everything from our ZIP code…

For decades, hospital pricing in the US was confusing and inconsistent – sometimes blindsiding patients when the bill arrived. That finally began to change when the Centers for Medicare & Medicaid Services (CMS) hospital price transparency law was introduced in 2021. It mandated that every hospital must publish a machine-readable file (MRF) containing up-to-date prices…

Generic drugs don’t usually grab headlines. They’re dependable, low-cost and mostly stay in the background. But behind that generic label is a global system that’s far more fragile, and far more important, than it seems. Today, that system is under serious pressure. The United States is facing everything from supply chain disruptions and political instability…

During a June 9 webinar hosted by Becker’s Payer Issues in collaboration with  PurpleLab, leaders from Payerset, PurpleLab and Forvis Mazars outlined how health systems can use price transparency data to improve contract negotiations, support market expansion strategies and prepare for upcoming changes in drug pricing rules.   Four Key Takeaways: 1.Price transparency data as…

This research, led by Grace K. Kane, Douglas Londono, and Nathan J. Markward, explores how the timing of biomarker testing affects survival outcomes in patients with non-small cell lung cancer (NSCLC). Using real-world claims data, it identifies disparities in testing and treatment patterns and their impact on mortality rates. Biomarker testing is essential to advancing…

At ISPOR 2025 in Montreal, PurpleLab presented a research poster titled “Trends in Attainment of the Kidney Health Evaluation for Patients with Diabetes Measure among Insured Individuals in the US, 2021-2024”. The study, conducted by Stephan Dunning, MBA, MS, Douglas Londono, PhD, Yeison Ortiz, BS, Anna Wang, PhD, Nathan Markward, PhD, MPH, and Steven Emrick, BS,…

At ISPOR 2025 in Montreal, PurpleLab presented a research poster titled “Intersectional Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA) for Social Determinants of Health and Pregnancy Outcomes.” The study, conducted by Anna Wang, PhD, Francis Concannon, BS, Daria Eremina, PhD, and Douglas Londono, PhD, applied MAIHDA to analyze how overlapping social factors influence…

Pharma advertising measurement has been stuck in the past. But it doesn’t have to be.  For years, pharma marketers have been stuck chasing the wrong numbers. Impressions. Clicks. Bounce rates. The list goes on. These vanity metrics might look good on a dashboard, but they don’t tell you if your campaign actually moved the needle….